Ningbo MedicalSystem Financials
| 300439 Stock | 11.43 0.05 0.44% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 283.2 M | 253 M |
|
|
Ningbo | Select Account or Indicator |
Understanding current and past Ningbo MedicalSystem Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ningbo MedicalSystem's financial statements are interrelated, with each one affecting the others. For example, an increase in Ningbo MedicalSystem's assets may result in an increase in income on the income statement.
Please note, the presentation of Ningbo MedicalSystem's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ningbo MedicalSystem's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ningbo MedicalSystem's management manipulating its earnings.
Ningbo MedicalSystem Stock Summary
Ningbo MedicalSystem competes with Industrial, China Construction, Agricultural Bank, Bank of China, and PetroChina. Ningbo MedicalSystem is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE100001Z25 |
| Business Address | No299, Qiming South |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.nbmksw.com |
| Phone | 86 574 5533 7009 |
You should never invest in Ningbo MedicalSystem without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Ningbo Stock, because this is throwing your money away. Analyzing the key information contained in Ningbo MedicalSystem's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Ningbo MedicalSystem Key Financial Ratios
Ningbo MedicalSystem's financial ratios allow both analysts and investors to convert raw data from Ningbo MedicalSystem's financial statements into concise, actionable information that can be used to evaluate the performance of Ningbo MedicalSystem over time and compare it to other companies across industries.| Revenue | 1.89 B | ||||
| Gross Profit | 949.62 M | ||||
| EBITDA | 330.95 M | ||||
| Net Income | 256.55 M | ||||
| Total Asset | 3.49 B |
Ningbo MedicalSystem Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 3.7B | 3.3B | 3.6B | 3.6B | 3.5B | 2.8B | |
| Other Current Liab | 415.8M | 162.8M | 189.5M | 293.1M | 10.1M | 9.6M | |
| Other Liab | 50.1M | 80.5M | 70.6M | 48.9M | 56.3M | 56.9M | |
| Retained Earnings | 426.8M | 753.4M | 872.8M | 1.0B | 1.1B | 720.5M | |
| Accounts Payable | 281.9M | 277.2M | 331.3M | 374.3M | 333.5M | 199.3M | |
| Cash | 436.6M | 328.2M | 666.3M | 806.4M | 958.9M | 487.9M | |
| Other Assets | 181.0M | 205.3M | 202.2M | 164.0M | 188.6M | 125.5M | |
| Net Receivables | 1.2B | 856.1M | 810.8M | 815.9M | 567.7M | 729.7M | |
| Inventory | 409.5M | 253.9M | 211.4M | 218.0M | 259.0M | 250.1M | |
| Other Current Assets | 85.7M | 61.4M | 157.7M | 74.9M | 24.6M | 23.4M | |
| Total Liab | 2.4B | 1.6B | 1.2B | 1.1B | 782.5M | 1.1B | |
| Intangible Assets | 171.6M | 163.4M | 148.4M | 120.2M | 127.8M | 131.4M | |
| Common Stock | 346.4M | 345.3M | 343.0M | 383.0M | 440.4M | 302.0M | |
| Net Tangible Assets | 1.1B | 1.5B | 2.2B | 2.4B | 2.7B | 1.5B | |
| Total Current Assets | 2.1B | 1.6B | 2.0B | 2.1B | 1.9B | 2.1B | |
| Long Term Debt | 243.0M | 97.0M | 45.0M | 7.0M | 6.3M | 6.0M | |
| Good Will | 173.3M | 836.5M | 16.4M | 13.6M | 12.2M | 11.6M | |
| Short Long Term Debt | 1.2B | 782.4M | 340.2M | 217.8M | 50.1M | 47.6M | |
| Net Invested Capital | 2.8B | 2.5B | 2.7B | 2.7B | 2.8B | 2.2B | |
| Net Working Capital | 72.1M | 180.4M | 948.7M | 1.1B | 1.2B | 680.6M |
Ningbo MedicalSystem Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 81.4M | 55.1M | 29.3M | 15.6M | 10.7M | 10.1M | |
| Total Revenue | 3.1B | 2.3B | 2.3B | 2.5B | 1.9B | 1.8B | |
| Operating Income | 377.0M | 268.6M | 295.9M | 312.8M | 253.0M | 283.2M | |
| Cost Of Revenue | 2.1B | 1.5B | 1.3B | 1.5B | 1.0B | 1.1B | |
| Income Before Tax | (525.1M) | 347.0M | 218.2M | 223.3M | 295.7M | 184.2M | |
| Net Income | (559.9M) | 299.5M | 179.5M | 198.5M | 256.6M | 137.3M | |
| Income Tax Expense | 51.6M | 53.5M | 28.1M | 18.1M | 20.8M | 19.8M | |
| Research Development | 128.3M | 135.5M | 150.7M | 171.8M | 149.8M | 128.8M | |
| Gross Profit | 1.1B | 848.3M | 911.3M | 949.6M | 841.2M | 920.1M | |
| Ebit | 324.6M | 265.7M | 266.7M | 264.6M | 238.1M | 243.4M | |
| Minority Interest | 51.1M | 45.3M | (10.7M) | (6.7M) | (2.9M) | (2.8M) | |
| Tax Provision | 51.6M | 53.5M | 28.1M | 18.1M | 36.2M | 38.0M | |
| Net Interest Income | (80.1M) | (53.5M) | (23.2M) | (9.2M) | 2.4M | 2.5M | |
| Interest Income | 1.9M | 2.6M | 6.7M | 7.5M | 13.3M | 13.9M | |
| Ebitda | (282.2M) | 575.7M | 442.3M | 430.6M | 495.2M | 408.1M |
Ningbo MedicalSystem Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Ningbo MedicalSystem. It measures of how well Ningbo is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Ningbo MedicalSystem brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Ningbo had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Ningbo MedicalSystem has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Dividends Paid | 128.6M | 125.4M | 91.4M | 50.7M | 49.9M | 69.4M | |
| Capital Expenditures | 363.2M | 383.4M | 201.8M | 303.1M | 280.4M | 274.7M | |
| Net Income | (559.9M) | 299.5M | 179.5M | 198.5M | 256.6M | 139.0M | |
| Change To Inventory | (44.6M) | 81.8M | 15.3M | (20.7M) | (58.0M) | (60.9M) | |
| Investments | (3.6M) | 9.2M | (47.3M) | 19.6M | (162.1M) | (154.0M) | |
| Change In Cash | 21.1M | (115.3M) | 353.1M | 109.5M | 168.5M | 95.6M | |
| Net Borrowings | 213.1M | (621.9M) | (472.5M) | (149.2M) | (134.3M) | (127.6M) | |
| Depreciation | 161.5M | 173.5M | 187.2M | 191.7M | 169.6M | 153.6M | |
| Change To Netincome | 887.9M | 91.6M | 90.2M | 102.1M | 117.4M | 196.4M | |
| End Period Cash Flow | 436.6M | 321.3M | 674.3M | 783.9M | 952.3M | 578.7M | |
| Free Cash Flow | 238.0M | 528.6M | 313.7M | 261.5M | 353.2M | 177.1M | |
| Other Non Cash Items | 115.5M | 87.9M | 62.4M | 35.6M | 25.8M | 24.5M |
Ningbo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ningbo MedicalSystem's current stock value. Our valuation model uses many indicators to compare Ningbo MedicalSystem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ningbo MedicalSystem competition to find correlations between indicators driving Ningbo MedicalSystem's intrinsic value. More Info.Ningbo MedicalSystem Biotechnology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.37 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Ningbo MedicalSystem Biotechnology is roughly 2.68 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Ningbo MedicalSystem by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ningbo MedicalSystem's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Ningbo MedicalSystem Systematic Risk
Ningbo MedicalSystem's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ningbo MedicalSystem volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Ningbo MedicalSystem correlated with the market. If Beta is less than 0 Ningbo MedicalSystem generally moves in the opposite direction as compared to the market. If Ningbo MedicalSystem Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ningbo MedicalSystem is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ningbo MedicalSystem is generally in the same direction as the market. If Beta > 1 Ningbo MedicalSystem moves generally in the same direction as, but more than the movement of the benchmark.
Ningbo MedicalSystem Biotechnology Total Assets Over Time
Ningbo MedicalSystem Thematic Clasifications
Ningbo MedicalSystem Biotechnology is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Ningbo MedicalSystem November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ningbo MedicalSystem help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ningbo MedicalSystem Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ningbo MedicalSystem Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Ningbo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ningbo MedicalSystem's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.85 | |||
| Information Ratio | 0.051 | |||
| Maximum Drawdown | 23.23 | |||
| Value At Risk | (3.34) | |||
| Potential Upside | 4.72 |
Complementary Tools for Ningbo Stock analysis
When running Ningbo MedicalSystem's price analysis, check to measure Ningbo MedicalSystem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ningbo MedicalSystem is operating at the current time. Most of Ningbo MedicalSystem's value examination focuses on studying past and present price action to predict the probability of Ningbo MedicalSystem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ningbo MedicalSystem's price. Additionally, you may evaluate how the addition of Ningbo MedicalSystem to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |